Our participation in the American College of Cardiology 64th annual Scientific Sessions last month in San Diego appears to have been very successful. The traffic to our booth was extremely high and a large number of visitors, from the United States and overseas, expressed interest in our products. Attendees were curious in our core technology EECP® (Enhanced External Counterpulsation) therapy and our growing patient monitoring product line.
Additionally, Dr. Joseph Tartaglia on behalf of his co-authors from the New York Medical College in Valhalia, New York presented a poster abstract on EECP® Therapy and the positive effect it has on decreasing the risk of Major Adverse Cardiac Events (referred to as MACE) for patients. The poster was titled “Patients That Respond to Enhanced External Counterpulsation Are at Decreased Risk for Major Adverse Cardiac Events and Have Increases in Endothelial Precursor Stem Cells”. The study, which followed up on the participating patients for 96 months, demonstrated that these patients had an increase in exercise capacity post treatment and had fewer major adverse cardiac events after treatment. It showed that patients with increased exercise capacity also had an increase in peripheral endothelial precursor CD133+ cells. This suggests, according to the authors, that the new collateral vessel development resulting from the EECP® treatment is responsible for the improved outcomes.
Our next exhibition will be at the Hospitalar meeting in Sao Paulo, Brazil in May. We look forward to showcase our EECP Therapy and our patient monitoring product line to the growing medical industry in Latin America.
We’ve just departed from Dubai having completed a very successful Arab Health exposition. The Vasomedical booth included displays, graphics and demonstrations from all segments of our company profile, including EECP® and ECP therapy systems, Biox’ new ECG Holter and ambulatory blood pressure monitors and our wireless MobiCare™ patient monitoring products. Our booth location was ideal, we were in one of the convention center’s main concourses and was extremely busy throughout the whole show. We were joined in the booth by our associates from Biox and VSK, Vasomedical’s newest joint venture for marketing and sales of EECP/ECP technology globally. Together we welcomed many visitors from all over the Middle East, as well as visitors from North America, Europe and India.
This show allowed us to increase our exposure in the Middle East. There are treatment centers in the Kingdom of Saudi Arabia, the United Arab Emirates, Egypt, Jordan, the Sudan, Bahrain, Oman and Israel. Many physicians in the region are familiar with the clinical benefits of the therapy and are very interested in bringing the technology to their local hospitals and clinics.
Biox – MobiCare™ wireless patient monitoring products attracted a high level of interest at the show. The flexibility to un-tether the patient from the monitor using Bluetooth technology is very unique. Along with the added feature of remote viewing capabilities away from the clinical setting by physicians, healthcare workers and patient families, it was evident that MobiCare™ was one of the most interesting new products seen by many of the attendees.